Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
PEG-Intron Observation After Regional Lymph Node Dissection in AJCC Stage III (TxN1-2MO) Melanoma Patients: a Randomized Phase III Trial
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells. It is not yet known if this treatment is more effective than observation following surgery for stage III melanoma.
PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa in treating patients who have undergone surgery for stage III melanoma.
調査の概要
詳細な説明
OBJECTIVES:
- Compare the effect of adjuvant therapy with pegylated interferon alfa vs observation, in terms of distant metastases-free survival, in patients with previously resected stage III melanoma.
- Compare the overall survival in these patients after treatment with pegylated interferon alfa vs observation.
- Determine the toxicity of pegylated interferon alfa in these patients.
- Determine the compliance of these patients treated with pegylated interferon alfa.
- Compare the quality of life in these patients after treatment with pegylated interferon alfa vs observation.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to type of nodal involvement (N1 vs N2), number of positive nodes (1 vs 2-4 vs 5 or more vs not assessed), Breslow primary (T1-2 vs T3 vs T4 vs unknown), ulceration of primary tumor (absent vs present vs unknown), sex, and center. Patients are randomized to one of two treatment arms.
- Arm I: Patients receive pegylated interferon alfa subcutaneously weekly for 5 years.
- Arm II: Patients undergo observation only. Treatment continues in the absence of distant metastases or unacceptable toxicity.
Quality of life is assessed at baseline, and then at months 3, 12, 24, 36, 48, and 60.
Patients are followed every 6 months for 5 years.
PROJECTED ACCRUAL: A total of 1,200 patients (600 per treatment arm) will be accrued for this study within 1.5-2 years.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
-
Birmingham、イギリス、B29 6JD
- Selly Oak Hospital at University Hospital NHS Trust
-
Oxford、イギリス、OX3 7LJ
- Churchill Hospital
-
-
England
-
Bristol、England、イギリス、BS2 8ED
- Bristol Haematology and Oncology Centre
-
Cambridge、England、イギリス、CB2 2QQ
- Addenbrooke's NHS Trust
-
Cheltenham、England、イギリス、GL53 7AN
- Cheltenham General Hospital
-
Exeter、England、イギリス、EX2 5DW
- Royal Devon and Exeter Hospital
-
Guildford、England、イギリス、GU2 5XX
- Royal Surrey County Hospital
-
Hull、England、イギリス、HU8 9HE
- Princess Royal Hospital
-
Leeds、England、イギリス、LS9 7TF
- St. James's Hospital
-
Leicester、England、イギリス、LE1 5WW
- Leicester Royal Infirmary
-
London、England、イギリス、SW3 6JJ
- Royal Marsden NHS Trust
-
London、England、イギリス、NW3 2QG
- Royal Free Hospital
-
London、England、イギリス、SW17 0QT
- St. George's Hospital
-
London、England、イギリス、EC1A 7BE
- Saint Bartholomew's Hospital
-
London、England、イギリス、SE1 9RT
- Guy's and St. Thomas' Hospitals NHS Trust
-
Merseyside、England、イギリス、CH63 4JY
- Clatterbridge Centre for Oncology NHS Trust
-
Newcastle Upon Tyne、England、イギリス、NE4 6BE
- Newcastle General Hospital
-
Salisbury、England、イギリス、SP2 8BJ
- Salisbury District Hospital
-
Sheffield、England、イギリス、S1O 2SJ
- Weston Park Hospital
-
Southampton、England、イギリス、SO16 6YD
- Southampton General Hospital
-
Sutton、England、イギリス、SM2 5PT
- Royal Marsden Hospital
-
Westcliff-On-Sea、England、イギリス、SS0 0RY
- Southend NHS Trust Hospital
-
-
Northern Ireland
-
Belfast、Northern Ireland、イギリス、BT9 7AB
- Belfast City Hospital Trust
-
-
Scotland
-
Dundee、Scotland、イギリス、DD1 9SY
- Ninewells Hospital and Medical School
-
Glasgow、Scotland、イギリス、G11 6NT
- Western Infirmary
-
-
Wales
-
Cardiff、Wales、イギリス、CF4 7XL
- Velindre Cancer Center at Velinde Hospital
-
-
-
-
-
Haifa、イスラエル、31096
- Rambam Medical Center
-
Holon、イスラエル、58100
- Wolfson Medical Center
-
Tel-Aviv、イスラエル、64239
- Tel-Aviv Sourasky Medical Center
-
-
-
-
-
Aviano、イタリア、33081
- Centro di Riferimento Oncologico - Aviano
-
Firenze、イタリア、I-50011
- Ospendale S.M. Annunziata-A.S.DI Firenze
-
Genoa (Genova)、イタリア、16132
- Istituto Nazionale per la Ricerca sul Cancro
-
Milano、イタリア、20141
- European Institute of Oncology - Chemo Prevention
-
Milano (Milan)、イタリア、20133
- Istituto Nazionale per lo Studio e la Cura dei Tumori
-
Naples、イタリア、80131
- Istituto Nazionale per lo Studio e la Cura dei Tumori
-
Rome、イタリア、00161
- Istituto Regina Elena
-
Torino、イタリア、10126
- Universita Degli Studi di Torino
-
-
-
-
-
Tallinn、エストニア、11619
- North-Estonian Regional Hospital Cancer Centre
-
-
-
-
-
Amsterdam、オランダ、1007 MB
- Vrije Universiteit Medisch Centrum
-
Leiden、オランダ、2300 CA
- Leiden University Medical Center
-
Nijmegen、オランダ、NL-6500 HB
- University Medical Center Nijmegen
-
Rotterdam、オランダ、3075 EA
- Erasmus University Medical Center
-
Utrecht、オランダ、3584 CX
- Academisch Ziekenhuis Utrecht
-
-
-
-
-
Newcastle、オーストラリア、NSW 2300
- David Maddison Clincial Sciences
-
-
Victoria
-
East Melbourne、Victoria、オーストラリア、8006
- Peter Maccallum Cancer Institute
-
Heidelberg West、Victoria、オーストラリア、3081
- Austin and Repatriation Medical Centre
-
-
Western Australia
-
Perth、Western Australia、オーストラリア、6000
- Royal Perth Hospital
-
Perth、Western Australia、オーストラリア、6009
- Sir Charles Gairdner Hospital, Perth
-
-
-
-
-
Zagreb、クロアチア、10000
- University Hospital Sestre Milosrdnice
-
-
-
-
-
Aarau、スイス、5001
- Kantonspital Aarau
-
Bern、スイス、CH-3010
- Inselspital, Bern
-
Chur、スイス、CH-7000
- Ratisches Kantons und Regionalspital
-
Zurich、スイス、CH-8091
- UniversitaetsSpital
-
-
-
-
-
Madrid、スペイン、28041
- Hospital Universitario 12 de Octubre
-
Zaragoza、スペイン、50009
- Hospital Clinico Universitario
-
-
-
-
-
Ljubljana、スロベニア、Sl-1000
- Institute of Oncology, Ljubljana
-
-
-
-
-
Prague (Praha)、チェコ共和国、128 08
- Charles University Hospital
-
-
-
-
-
Berlin、ドイツ、D-13122
- Robert Roessle Klinik
-
Bochum 1、ドイツ、D-44791
- Saint Josef Hospital
-
Dortmund、ドイツ、44123
- Stadt. Kliniken
-
Erlangen、ドイツ、D-91054
- Universitaet Erlangen
-
Goettingen、ドイツ、D-37075
- Georg August Universitaet
-
Hamburg、ドイツ、D-22765
- Haematologisch-Onkologische Praxis Altona
-
Heidelberg、ドイツ、D-69115
- Universitaets-Hautklinik Heidelberg
-
Leipzig、ドイツ、D-04103
- Universitaet Leipzig - Chirurgische Klinik und Poliklinik I
-
Magdeburg、ドイツ、D-39120
- Otto - Von - Guericke - Universitaet Magdeburg
-
Mannheim、ドイツ、D-68135
- Klinikum der Stadt Mannheim
-
Wuerzburg、ドイツ、D-97080
- Universitaet Wuerzburg/Hautkrankheiten
-
-
-
-
-
Amiens、フランス、80054
- Centre Hospitalier Universitare d'Amens
-
Besancon、フランス、25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux、フランス、33075
- Hopital Saint André
-
Boulogne Billancourt、フランス、F-92104
- CHU Ambroise Paré
-
Grenoble、フランス、38043
- Chr De Grenoble - La Tronche
-
Lille、フランス、59037
- Centre Hospitalier Regional et Universitaire de Lille
-
Limoges、フランス、87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon、フランス、69373
- Centre Léon Bérard
-
Montpellier、フランス、34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Montpellier、フランス、34295
- Hopital St. Eloi
-
Nice、フランス、F-06202
- Hopital L'Archet - 2
-
Paris、フランス、75018
- Hopital Bichat - Claude Bernard
-
Paris、フランス、75475
- Hôpital Saint-Louis
-
Pessac、フランス、33604
- Hopital Haut Lévêque
-
Reims、フランス、51092
- Centre Hospitalier Universitaire
-
Rennes、フランス、35042
- Centre Eugene Marquis
-
Saint Cloud、フランス、92211
- Centre René Huguenin
-
Saint Priest en Jarez、フランス、42277
- Centre Hospitalier Regional et Universitaire de Saint-Etienne
-
Strasbourg、フランス、67091
- Hopitaux Universitaire de Strasbourg
-
Thionville、フランス、57126
- Centre Hospitalier Régional Metz Thionville
-
Tours、フランス、37044
- Centre Hospitalier Universitaire Bretonneau de Tours
-
Vandoeuvre-les-Nancy、フランス、54511
- Centre Alexis Vautrin
-
Villejuif、フランス、F-94805
- Institut Gustave Roussy
-
-
-
-
-
Sofia、ブルガリア、1756
- National Centre of Oncology
-
-
-
-
-
Brussels、ベルギー、1200
- Cliniques universitaires Saint-Luc
-
Brussels、ベルギー、1000
- Institut Jules Bordet
-
Brussels、ベルギー、1070
- Hopital Universitaire Erasme
-
Edegem、ベルギー、B-2650
- Universitair Ziekenhuis Antwerpen
-
Gosselies、ベルギー、6041
- Clinique Notre Dame de Grâce
-
Leuven、ベルギー、B-3000
- U.Z. Gasthuisberg
-
-
-
-
-
Lisbon、ポルトガル、1099-023 Codex
- Instituto Portugues de Oncologia de Francisco Gentil - Centro de Lisboa
-
Porto、ポルトガル、4200
- Instituto Portugues de Oncologia Centro do Porto, SA
-
-
-
-
-
Poznan、ポーランド、61 866
- Great Poland Cancer Center
-
Warsaw、ポーランド、02-781
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
-
-
-
-
-
Istanbul、七面鳥、34296
- Vakif Gureba Training Hospital
-
Izmir、七面鳥、35220
- Ege University Medical School
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
DISEASE CHARACTERISTICS:
Histologically confirmed previously resected stage III primary cutaneous melanoma or unknown primary with regional lymph node involvement
N1 disease
- Microscopic, nonpalpable nodal involvement
- Primary melanoma of any stage with clinically inapparent N1 regional lymph node metastases (T1-4, N1, M0) detected by elective lymph node dissection or sentinel node biopsy
N2 disease
- Palpable nodal involvement with synchronous primary melanoma or apparent nodal disease after prior excision (any pT, N2, M0)
- Regional lymph node recurrence at any interval after surgery for primary melanoma of any depth (T1-4, rN2, M0)
- Complete resection of primary melanoma with adequate surgical margins
- Full lymphadenectomy must be performed within 70 days of study
- No mucous membrane melanoma or ocular melanoma
- No evidence of distant or nonregional lymph node metastases or in transit metastases (even if previously resected)
- No incompletely resected disease due to gross extracapsular extension
PATIENT CHARACTERISTICS:
Age:
- 18 to 70
Performance status:
- ECOG 0-1
Life expectancy:
- Not specified
Hematopoietic:
- WBC at least 3,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin at least 9 g/dL
Hepatic:
- SGOT and SGPT less than 2 times upper limit of normal
- No active hepatitis
Renal:
- Creatinine less than 2.0 mg/dL
Cardiovascular:
No severe cardiovascular disease including the following:
- Arrhythmias requiring chronic treatment
- Congestive heart failure (New York Heart Association class III or IV)
- Symptomatic ischemic heart disease
Other:
- No other prior malignancy within the past 5 years except surgically cured nonmelanomatous skin cancer or carcinoma in situ of the cervix
- No thyroid dysfunction unresponsive to therapy
- No uncontrolled diabetes mellitus
- No active autoimmune disease
- No active and/or uncontrolled infection
- No history of neuropsychiatric disorder requiring hospitalization
- No known active alcohol or drug abuse
- HIV negative
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- No prior interferon alfa
- No prior immunotherapy for melanoma
- No other concurrent immunologic or biologic therapy
- No concurrent colony stimulating factors including epoetin alfa and filgrastim (G-CSF)
Chemotherapy:
- No prior chemotherapy for melanoma
- No concurrent chemotherapy
Endocrine therapy:
- No prior hormonal therapy for melanoma
- No concurrent hormonal therapy
- No concurrent chronic systemic corticosteroid therapy
Radiotherapy:
- No prior radiotherapy for melanoma
- No concurrent radiotherapy
Surgery:
- See Disease Characteristics
- Recovered from any prior recent surgery
Other:
- At least 30 days since other prior experimental therapy
- No other concurrent investigational drugs
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
介入なし:observation
5 years observation + 5 years follow up
|
|
|
実験的:pegylated interferon alfa
5 years pegylated interferon alfa + 5 years follow up
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
distant-metastasis free-survival (DMFS)
時間枠:from randomization
|
distant-metastasis free-survival (DMFS) after randomization
|
from randomization
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
survival
時間枠:from randomization till death
|
duration of survival: time from randomization until death, whatever the cause
|
from randomization till death
|
|
toxicity
時間枠:from randomization
|
toxicity
|
from randomization
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
quality of life
時間枠:from randomization
|
Quality of life evaluation
|
from randomization
|
協力者と研究者
捜査官
- スタディチェア:Alexander M. M. Eggermont, MD, PhD、Daniel Den Hoed Cancer Center at Erasmus Medical Center
出版物と役立つリンク
一般刊行物
- Eggermont AM, Suciu S, Testori A, Kruit WH, Marsden J, Punt CJ, Santinami M, Sales F, Schadendorf D, Patel P, Dummer R, Robert C, Keilholz U, Yver A, Spatz A. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer. 2012 Jan;48(2):218-25. doi: 10.1016/j.ejca.2011.09.028. Epub 2011 Nov 5.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. [Abstract] J Clin Oncol 29 (Suppl 15): A-8506b, 2011.
- Bouwhuis MG, Suciu S, Testori A, Kruit WH, Sales F, Patel P, Punt CJ, Santinami M, Spatz A, Ten Hagen TL, Eggermont AM. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. J Clin Oncol. 2010 May 10;28(14):2460-6. doi: 10.1200/JCO.2009.24.6264. Epub 2010 Apr 12.
- Eggermont AM, Bouwhuis MG, Kruit WH, Testori A, ten Hagen T, Yver A, Xu C. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991). Cancer Chemother Pharmacol. 2010 Mar;65(4):671-7. doi: 10.1007/s00280-009-1072-z. Epub 2009 Jul 21.
- Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Sales F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009 Jun 20;27(18):2916-23. doi: 10.1200/JCO.2008.20.2069. Epub 2009 May 11. Erratum In: J Clin Oncol. 2009 Sep 20;27(27):4630. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.
- Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U. Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study). Eur J Cancer. 2009 Dec;45(18):3189-97. doi: 10.1016/j.ejca.2009.09.004. Epub 2009 Sep 28.
- Eggermont AM, Suciu S, Santinami M, Testori A, Kruit WH, Marsden J, Punt CJ, Sales F, Gore M, MacKie R, Kusic Z, Dummer R, Hauschild A, Musat E, Spatz A, Keilholz U; EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117-126. doi: 10.1016/S0140-6736(08)61033-8.
- Eggermont AM, Suciu S, Santinami M, et al.: EORTC 18991: long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-8504, 473s, 2007.
研究記録日
主要日程の研究
研究開始
一次修了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (見積もり)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。